Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global low-input sequencing technologies market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.
The low-input sequencing technologies market is primarily driven by growing research and development activities, as well as the increasing prevalence of rare and genetic disorders. The increasing awareness of prenatal testing to prevent, diagnose, and treat congenital disorders promotes the use of low-input sequencing technologies. Prominent market leaders collaborate and provide funding to support advanced genomic techniques. Technological advancements, such as automation and the adoption of innovative sequencing technologies, drive the market's future.
| Metric | Details |
| Market Overview | Expected significant growth from 2025–2034 driven by tech advancements and demand for rare disease diagnostics. |
| Key Drivers | Rising prevalence of rare/genetic disorders, prenatal testing awareness, and strong R&D activities. |
| Key Technologies | Next-generation sequencing (NGS) led in 2024; long-read sequencing expected fastest growth. |
| Applications | Clinical diagnostics led the market in 2024; precision/consumer genomics expected highest CAGR. |
| End-Users | Academic & government institutes dominated and are expected to grow rapidly due to skilled professionals and funding. |
| Regional Highlights | North America led in 2024; Asia-Pacific shows fastest growth due to rare disease prevalence and government support. |
Low-input sequencing technologies are techniques that enable genomic analyses on samples with limited amounts of starting material. Sequencing of rare samples, such as clinical biopsies and embryos, is crucial for understanding the mechanisms of development and disease. The low-input sequencing technologies are widely used in whole genome amplification, DNA methylation, chromatin accessibility, and transcriptomics. They are applied in embryonic development, prenatal and preimplantation genetic testing, oncology, and immunology.
The rising prevalence of rare disorders, combined with growing research and development activities, promotes the use of low-input sequencing technologies. Advancements in genomic technologies drive the latest innovations in genomic sequencing methodologies. The increasing investments and collaboration among academic researchers and key players contribute to market growth. The growing demand for early disease diagnosis and personalized medicines augments the market.
Artificial intelligence (AI) plays a vital role in low-input sequencing technologies by introducing automation and enhancing efficiency and precision. AI can lead to improved selectivity and accuracy of sequencing technologies. It can streamline the entire laboratory workflow and aid in quality control. AI and machine learning (ML) algorithms can analyze vast amounts of data and help researchers in data analysis. They can remove biases in research data and accelerate the speed of sequencing technologies. AI enables researchers to study disease progression easily. It allows clinicians to study individual patient conditions and develop personalized medicines.
Rising Prevalence of Rare Disorders
The major growth factor of the low-input sequencing technologies market is the rising prevalence of rare disorders. Rare disorders occur in a limited population. The World Health Organization (WHO) defines a rare disease occurs in fewer than 65 per 100,000 individuals. Rare diseases are estimated to affect around 3.5% to 5.9% of the global population, accounting for 260 to 440 million people globally. Approximately 72% of all rare diseases are of genetic origin. Cell sample analysis for rare diseases becomes difficult due to the limited availability of sample quantities. Hence, low-input sequencing technologies are used to evaluate genomic sequencing even with minimal starting material.
Lack of Skilled Professionals
Several research institutes in developing and underdeveloped countries lack skilled professionals to perform complex genomics research. Some researchers are unable to use advanced genomic techniques for various purposes and isolate single cells for genetic testing research.
What is the Future of the Low-Input Sequencing Technologies Market?
The future of the market is promising, driven by advancements in genomic technologies and personalized treatment. Low-input sequencing technologies have been used to study single-cell characterization. Integrating single-cell RNA sequencing techniques with large-scale technologies enhances the capabilities of these technologies. Some common examples of large-scale genetic technologies include CRISPR and LinTIMaT techniques. This enables the integration of transcriptional factors by deleting numerous genes. The use of low-input sequencing technologies with routine clinical examination strategies and personalized treatment mechanisms also presents future opportunities for market growth. This helps researchers understand disease pathogenesis and therapeutic markers.
By technology, the next-generation sequencing (NGS) segment led the global market in 2024. This segment dominated due to its ability to understand cellular heterogeneity and expanded applications in diverse fields. NGS is widely used in clinical diagnostics, cancer genomics, and microbial genomics. It enables a deeper understanding of cellular processes and disease mechanisms, enabling researchers to develop personalized treatments. Researchers are constantly making efforts to develop portable NGS platforms for their utilization in diagnosis. The major benefits of NGS include lower sample input requirements and higher accuracy.
By technology, the long-read sequencing segment is expected to grow at the fastest CAGR in the market during the forecast period. Long-read sequencing includes PacBio’s SMRT and Oxford’s Nanopore sequencing. It enables researchers to sequence longer DNA fragments, allowing them to detect structural variants within the genome. It is widely used as it offers improved accuracy for detecting specific types of variants. It also eliminates the amplification bias associated with short-read sequencing.
By product/consumable type, the consumables segment held a dominant presence in the market in 2024. Consumables, such as kits and reagents, are essential components to perform genomic sequencing research. Numerous biotech companies provide a wide range of consumables based on the type of experiment. This enables researchers to fulfill their research requirements and perform multiple experiments simultaneously. The availability of cost-effective consumables also boosts the segment’s growth.
By product/consumable type, the services & software segment is expected to grow with the highest CAGR in the market during the studied years. Services eliminate the need for researchers to purchase complex instruments and consumables for research. Some research labs from developing and underdeveloped countries prefer outsourcing their sequencing technologies due to a lack of favorable infrastructure and skilled personnel to perform research. Services provide relevant expertise and customization based on requirements.
By application, the clinical diagnostics segment held the largest revenue share of the market in 2024. Low-input sequencing technologies are widely used for the diagnosis of oncology and rare disorders. The oncology segment held a major share of the clinical diagnostics segment. The rising prevalence of cancer and the growing need for early cancer diagnosis augment the segment’s growth. According to the International Agency for Research on Cancer, fewer than 6 per 100,000 people annually are diagnosed with rare cancer types.
By application, the precision/consumer genomics segment is expected to witness the fastest growth in the market over the forecast period. Technological advancements lead to the development of portable devices incorporating low-input sequencing technologies. This enables consumers for direct genetic testing. The demand for personalized medicines is increasing due to rapidly changing demographics and the need for effective treatments. Researchers are also developing point-of-care diagnostics, providing a preliminary idea of a disease.
By end-user, the academic & government institutes segment contributed the biggest revenue share of the market in 2024 and is expected to expand rapidly in the market in the coming years. The segmental growth is attributed to the presence of skilled professionals and favorable infrastructure. The increasing investments and grants by government and private organizations for research in these institutes also support the segment’s growth. The growing research and development activities, along with the rising collaboration among researchers, promote genomic research.
North America dominated the global market in 2024. The presence of key players and the availability of state-of-the-art research and development facilities are the major growth factors of the market in North America. Technological advancements and a robust healthcare infrastructure encourage healthcare organizations to adopt innovative diagnostic tools. Several government organizations launch initiatives and provide funding for genomic sequencing research.
Key players, such as Illumina, PacBio, and Integrated DNA Technologies, are the major contributors to the market in the world. The National Human Genome Research Institute (NHGRI) promotes genomic sequencing research through research grants. The FY 2025 President’s Budget request for genomics and medicine is $663 million, an increase of 0.5% from 2023.
The Canadian government launched the Canadian Genomic Strategy (CGS) to advance commercialization and adoption of genomics applications, as well as strengthen leadership of the genomic enterprise to foster collaboration. The federal government announced an investment of $175.1 million over 7 years (2024-25 to 2031-32) to support the CGS.
Asia-Pacific is expected to grow at the fastest CAGR in the low-input sequencing technologies market during the forecast period. The rising prevalence of rare disorders and increasing investment by government or private organizations boost the market. Numerous research institutions and private companies organize conferences, workshops, and seminars to train individuals with advanced sequencing technologies and create awareness. The burgeoning biotech sector and the rising number of biotech startups also contribute to market growth.
In China, more than 20 million people are estimated to have rare diseases. The Asia-Pacific Alliance of Rare Disease Organizations (APARDO) recently organized the first-ever EU-China Rare Disease Policy and Access Summit in Dublin, Ireland, bringing together experts from Europe and China.
It is estimated that 50 to 100 million Indians are affected by rare diseases. The Indian government allocated around Rs 974 crore for the 2024-26 under the National Fund for Rare Diseases. The Indian government recently announced a future target of sequencing 10 million genomes to accelerate India’s advancements in genomics and personalized medicine.
Europe is expected to grow at a notable CAGR in the low-input sequencing technologies market in the foreseeable future. The growing demand for personalized medicines and increasing research and development activities drive the market. The rising adoption of advanced technologies enables researchers to develop innovative diagnostic tools and study disease progression. The government supports genomics research through initiatives and funding. The recent research funding cut by the Trump Administration opens doors for American scientists in Europe to perform advanced research.
The increasing public-private partnerships among key players and government organizations propel the market. In November 2024, Oxford Nanopore announced a collaboration with UK Biobank, Genomics England, and NHS England. The collaboration was made to support the government’s vision by enabling genomics-based translational research and accelerating the development and adoption of Oxford Nanopore’s ground-breaking genomics technology. (Source - Oxford Nanopore)
Charlie Roco, Chief Technology Officer and Co-founder of Parse Biosciences, commented on the launch of Evercode Low Input Fixation Kits for both cells and nuclei that the kits are another step toward providing the research community with greater access and flexibility for conducting single-cell studies. (Source - BioSpace)
By Technology
By Product/Consumable Type
By Application
By End-User
By Region
June 2025
May 2025
May 2025
April 2025